Advertisement

Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study

  • Makoto Sakai
  • Makoto SohdaEmail author
  • Hideyuki Saito
  • Kengo Kuriyama
  • Tomonori Yoshida
  • Yuji Kumakura
  • Keigo Hara
  • Takehiko Yokobori
  • Tatsuya Miyazaki
  • Kazutoshi Murata
  • Shin-ei Noda
  • Takashi Nakano
  • Hiroyuki Kuwano
  • Ken Shirabe
Original Article
  • 28 Downloads

Abstract

Background

To evaluate the efficacy of docetaxel, cisplatin, and 5-fluorouracil as combination chemoradiotherapy (DCF-RT) for cervical esophageal cancer (CEC), we performed a retrospective analysis of CEC patients treated by DCF-RT at a single institution.

Methods

We conducted a single-center retrospective study. Twenty-one patients with CEC who underwent DCF-RT between 1999 and 2017 at our institute were included in this study. Chemotherapy consisted of intravenous docetaxel at 50 mg/m2 on day 1, intravenous CDDP at 60 mg/m2 on day 1, and intravenous 5-FU at 600 mg/m2 on days 1–4, repeated every 4 weeks for two cycles. Among the 21 patients, six were irradiated using three-dimensional conformal RT (3D- conformal RT) and 15 were treated using intensity-modulated RT (IMRT) consisting of 60 Gy in 30 fractions.

Results

The median follow-up period was 49.6 months (range 4.6–97.6). The overall complete response (CR) and local CR rates were 61.9% and 81.0% for all patients, and 76.9% and 84.6% for patients without hypopharyngeal and/or thoracic esophageal invasion, respectively. The 3-year overall survival (OS), progression-free survival (PFS), and local failure-free survival (LFFS) rates were 79.6, 52.4, and 74.7%, respectively. Grade 3–4 leucopenia developed in 12 patients (70.6%), neutropenia developed in 13 patients (81.2%), and mucositis developed in 2 patients (9.5%). There were no treatment-related deaths.

Conclusions

The 3-year OS and LFFS of patients who underwent DCF-RT were higher than those in the previous studies. Although the high rate of myelosuppression requires careful management, DCF-RT is a safe and effective modality for CEC.

Keywords

Cervical esophageal cancer Chemoradiotherapy DCF Prognosis 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest associated with this manuscript.

References

  1. 1.
    Sombeck MD, Parsons JT et al (1994) Management of cervical esophageal carcinoma. Semin Radiat Oncol 4:179–191.  https://doi.org/10.1053/SRAO00400179 CrossRefGoogle Scholar
  2. 2.
    Kuwano H, Nishimura Y, Oyama T et al (2015) Guidelines for diagnosis and treatment of carcinoma of the Esophagus April 2012 edited by the Japan esophageal society. Esophagus.  https://doi.org/10.1007/s10388-014-0465-1 Google Scholar
  3. 3.
    Ajani JA, D’Amico TA, Almhanna K et al (2015) Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw 13:194–227CrossRefGoogle Scholar
  4. 4.
    Yamada K, Murakami M, Okamoto Y et al (2006) Treatment results of radiotherapy for carcinoma of the cervical esophagus. Acta Oncol (Madr) 45:1120–1125.  https://doi.org/10.1080/02841860600609768 CrossRefGoogle Scholar
  5. 5.
    Zhang P, Xi M, Zhao L et al (2015) Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol 116:257–261.  https://doi.org/10.1016/j.radonc.2015.07.011 CrossRefGoogle Scholar
  6. 6.
    Zenda S, Kojima T, Kato K et al (2016) Multicenter phase 2 study of cisplatin and 5-fluorouracil with concurrent radiation therapy as an organ preservation approach in patients with squamous cell carcinoma of the cervical esophagus. Int J Radiat Oncol Biol Phys 96:976–984.  https://doi.org/10.1016/j.ijrobp.2016.08.045 CrossRefGoogle Scholar
  7. 7.
    Ito M, Kodaira T, Tachibana H et al (2017) Clinical results of definitive chemoradiotherapy for cervical esophageal cancer: comparison of failure pattern and toxicities between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy. Head Neck 39:2406–2415.  https://doi.org/10.1002/hed.24909 CrossRefGoogle Scholar
  8. 8.
    Minsky BD, Pajak TF, Ginsberg RJ et al (2002) INT 0123 (radiation therapy oncology Group 94-05) phase III trial of combined-Modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167–1174.  https://doi.org/10.1200/JCO.2002.20.5.1167 CrossRefGoogle Scholar
  9. 9.
    Kato K, Eguchi Nakajima T, Ito Y et al (2013) Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for stage II-III esophageal carcinoma. Jpn J Clin Oncol 43:608–615.  https://doi.org/10.1093/jjco/hyt048 CrossRefGoogle Scholar
  10. 10.
    Ishida K, Ando N, Yamamoto S et al (2004) Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan esophageal oncology group (JEOG)/Japan clinical oncology group trial (JCOG9516). Jpn J Clin Oncol 34:615–619.  https://doi.org/10.1093/jjco/hyh107 CrossRefGoogle Scholar
  11. 11.
    Miyazaki T, Sohda M, Tanaka N et al (2015) Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer. Cancer Chemother Pharmacol 75:449–455CrossRefGoogle Scholar
  12. 12.
    Japan Esophageal Society JE (2017) Japanese classification of esophageal cancer, 11th edition: part II and III. Esophagus 14:37–65.  https://doi.org/10.1007/s10388-016-0556-2 CrossRefGoogle Scholar
  13. 13.
    Sobin L, Gospodarowicz M WC (2009) TNM Classification of Malignant Tumours, 7th Edition. In: WileyGoogle Scholar
  14. 14.
    Cao C, Luo J, Gao L et al (2015) Definitive radiotherapy for cervical esophageal cancer. Head Neck 37:151–155.  https://doi.org/10.1002/hed.23572 CrossRefGoogle Scholar
  15. 15.
    Huang SH, Lockwood G, Brierley J et al (2008) Effect of concurrent high-dose cisplatin chemotherapy and conformal radiotherapy on cervical esophageal cancer survival. Int J Radiat Oncol 71:735–740.  https://doi.org/10.1016/j.ijrobp.2007.10.022 CrossRefGoogle Scholar
  16. 16.
    Zhao L, Zhou Y, Mu Y et al (2017) Patterns of failure and clinical outcomes of definitive radiotherapy for cervical esophageal cancer. Oncotarget.  https://doi.org/10.18632/oncotarget.15665 Google Scholar
  17. 17.
    Katori H, Tsukuda M (2005) Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck. Clin Oncol 17:148–152.  https://doi.org/10.1016/j.clon.2004.09.013 CrossRefGoogle Scholar
  18. 18.
    Tamaki Y, Hieda Y, Nakajima M et al (2018) Concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil improves survival of patients with advanced esophageal cancer compared with conventional concurrent chemoradiotherapy with cisplatin and 5-fluorouracil. J Cancer 9:2765–2772.  https://doi.org/10.7150/jca.23456 CrossRefGoogle Scholar
  19. 19.
    Bedford JL, Viviers L, Guzel Z et al (2000) A quantitative treatment planning study evaluating the potential of dose escalation in conformal radiotherapy of the oesophagus. Radiother Oncol 57:183–193CrossRefGoogle Scholar
  20. 20.
    Higuchi K, Komori S, Tanabe S et al (2014) Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys 89:872–879.  https://doi.org/10.1016/j.ijrobp.2014.03.030 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Makoto Sakai
    • 1
  • Makoto Sohda
    • 1
    Email author
  • Hideyuki Saito
    • 1
  • Kengo Kuriyama
    • 1
  • Tomonori Yoshida
    • 1
  • Yuji Kumakura
    • 1
  • Keigo Hara
    • 1
  • Takehiko Yokobori
    • 2
  • Tatsuya Miyazaki
    • 1
  • Kazutoshi Murata
    • 3
  • Shin-ei Noda
    • 4
  • Takashi Nakano
    • 3
  • Hiroyuki Kuwano
    • 1
    • 5
  • Ken Shirabe
    • 1
  1. 1.Department of General Surgical Science, Graduate School of MedicineGunma UniversityMaebashiJapan
  2. 2.Department of Innovative Cancer ImmunotherapyGunma University Graduate School of MedicineMaebashiJapan
  3. 3.Department of Radiation OncologyGunma University Graduate School of MedicineMaebashiJapan
  4. 4.Department of Radiation OncologyInternational Medical Center, Saitama Medical UniversitySaitamaJapan
  5. 5.Fukuoka City HospitalFukuokaJapan

Personalised recommendations